AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg (1- or 4-hour infusion every 8 hours)
Number of subjects: 1332
Study 19670912 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 1332
Study 19670912 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 1332
Study 19670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem for patients with seizure-predisposing conditions
Number of subjects: 1332
Study 19670912 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam for patients with seizure-predisposing conditions
Number of subjects: 1332
Study 19670912 — intervention group
Group type: COMPARATOR
Intervention: Imipenem for patients with seizure-predisposing conditions
Number of subjects: 1332
Study 19671016 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral procaine benzyl penicillin and an aminoglycoside
Number of subjects: 0
Study 19671016 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired neonatal bacteremia incidence
Number of subjects: 0
Study 19671016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 0
Study 19671016 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic resistance
Number of subjects: 0
Study 19671016 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection timing
Number of subjects: 0
Study 19671733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleandrin treatment
Number of subjects: 0
Study 19671733 — intervention group
Group type: COMPARATOR
Intervention: Knocking down alpha3 isoform with alpha3 siRNA
Number of subjects: 0
Study 19671733 — intervention group
Group type: COMPARATOR
Intervention: Increasing expression of alpha1 isoform through transient transfection of alpha1 cDNA
Number of subjects: 0
Study 19671733 — intervention group
Group type: COMPARATOR
Intervention: Rodent cancer cells
Number of subjects: 0
Study 19675988 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered knee prosthesis with two series-elastic actuators in an agonist-antagonist arrangement
Number of subjects: 0
Study 19675988 — intervention group
Group type: COMPARATOR
Intervention: Weight- and height-matched nonamputee
Number of subjects: 0
Study 19676128 — intervention group
Group type: COMPARATOR
Intervention: None (no coffee consumption)
Number of subjects: 766
Study 19676128 — intervention group
Group type: COMPARATOR
Intervention: Less than 1 cup/day
Number of subjects: 766
Study 19676128 — intervention group
Group type: COMPARATOR
Intervention: 1 to fewer than 3 cups/day
Number of subjects: 766
Study 19676128 — intervention group
Group type: COMPARATOR
Intervention: 3 or more cups/day
Number of subjects: 766
Study 19679246 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip system
Number of subjects: 107
Study 19679693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting MPAP above the median (17 mm Hg)
Number of subjects: 29
Study 19679693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting pulmonary vascular resistance
Number of subjects: 29
Study 19679693 — intervention group
Group type: EXPERIMENTAL
Intervention: MPAP above the median at 25W and 50W
Number of subjects: 29
Study 19679693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index at peak exercise
Number of subjects: 29
Study 19679693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vascular resistance at peak exercise
Number of subjects: 29
Study 19679883 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (20 mg, thrice weekly for up to 12 weeks)
Number of subjects: 4
Study 19679883 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab (thrice-weekly, fractionated-dose)
Number of subjects: 4
Study 19683108 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endoscopy in patients with CAD
Number of subjects: 100
Study 19683270 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Number of subjects: 27
Study 19683270 — intervention group
Group type: COMPARATOR
Intervention: Standard hematoxylin and eosin analysis
Number of subjects: 27
Study 19685102 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with myocardial ischemia
Number of subjects: 305
Study 19685102 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with carotid arterial disease
Number of subjects: 305
Study 19685102 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with peripheral arterial disease
Number of subjects: 305
Study 19685102 — intervention group
Group type: COMPARATOR
Intervention: Reference subjects (nondiabetic)
Number of subjects: 305
Study 19687399 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with porfimer sodium (2 mg/kg, injected intravenously 48 hours before treatment) and light at 630 nm (50 J/cm² for dysplasia and CIS, 75 J/cm² for carcinoma)
Number of subjects: 30
Study 19687399 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with porfimer sodium
Number of subjects: 30
Study 19687424 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 62
Study 19688336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (normal, mild dysfunction, severe dysfunction)
Number of subjects: 11140
Study 19688336 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cognitive dysfunction
Number of subjects: 11140
Study 19689789 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-estrogen therapy (Tamoxifen for premenopausal women, Letrozole for postmenopausal women)
Number of subjects: 23
Study 19689789 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not undergo preoperative anti-estrogenic treatment)
Number of subjects: 23
Study 19690058 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m(2) b.i.d. for 2 weeks followed by capecitabine 575-650 mg/m(2) b.i.d. and cisplatin 20-25 mg/m(2) i.v. weekly during chemoradiotherapy
Number of subjects: 31
Study 19692493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein (HC)
Number of subjects: 21
Study 19692493 — intervention group
Group type: COMPARATOR
Intervention: Intact casein (IC)
Number of subjects: 21
Study 19692493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IC and HC
Number of subjects: 21
Study 19692879 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HA) during videolaparocholecystectomy (VLC)
Number of subjects: 101
Study 19692879 — intervention group
Group type: COMPARATOR
Intervention: Control group (VLC without HA)
Number of subjects: 101
Study 19694588 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine initiative for stroke care
Number of subjects: 24
Study 19694588 — intervention group
Group type: COMPARATOR
Intervention: Current stroke care practices
Number of subjects: 24
Study 19694588 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed 5-year stroke telemedicine plan
Number of subjects: 24
Study 19694588 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic coverage and operating costs
Number of subjects: 24
Study 19695539 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Express stents implantation
Number of subjects: 441
Study 19696651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in acute HIV-1 infection
Number of subjects: 121
Study 19696651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in recent HIV-1 infection
Number of subjects: 121
Study 19696651 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 121
Study 19696651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline viral load <100,000/ml
Number of subjects: 121
Study 19696651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline viral load >100,000/ml
Number of subjects: 121
Study 19697416 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free (PF) hepatitis B vaccine
Number of subjects: 541
Study 19697416 — intervention group
Group type: COMPARATOR
Intervention: Preservative-containing (PC) hepatitis B vaccine
Number of subjects: 541
Study 19697416 — intervention group
Group type: COMPARATOR
Intervention: Low-preservative (LP) hepatitis B vaccine
Number of subjects: 541
Study 19697416 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study after 6 years
Number of subjects: 541
Study 19698154 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-mediated walking program (Stepping Up to Health)
Number of subjects: 880
Study 19698185 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Chronic Care Model (CCM) program for type 2 diabetes patients.
Number of subjects: 2300
Study 19698185 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a local steering group and appointment of a program manager.
Number of subjects: 2300
Study 19698185 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-trained and motivated care providers investing in quality improvement.
Number of subjects: 2300
Study 19698185 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexity of the intervention, lack of quality data, inadequate information technology support, lack of commitment procedures, uncertainty about sustainable funding.
Number of subjects: 2300
Study 19698816 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg, taken continuously for three 28-day intervals.
Number of subjects: 58
Study 19700662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic T lymphocyte (CTL) therapy with specificity for Epstein-Barr virus (EBV) and adenovirus (5 x 10(6)-1.35 x 10(8) cells/m(2))
Number of subjects: 13
Study 19700662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic T lymphocyte (CTL) therapy with specificity for adenovirus
Number of subjects: 13
Study 19701032 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pelvic and groin radiation (45-50 Gy, n=59)
Number of subjects: 114
Study 19701032 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral pelvic node resection (n=55)
Number of subjects: 114
Study 19703299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5-1.2 mg/kg/day)
Number of subjects: 159
Study 19703304 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week subcutaneously
Number of subjects: 307
Study 19703304 — intervention group
Group type: COMPARATOR
Intervention: Control group (OASIS cohort)
Number of subjects: 307
Study 19703304 — intervention group
Group type: COMPARATOR
Intervention: Control group (OASIS-Eligible cohort)
Number of subjects: 307
Study 19704093 — intervention group
Group type: EXPERIMENTAL
Intervention: 320-row computed tomography (CT)
Number of subjects: 30
Study 19704101 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1100
Study 19704101 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Mass Index
Number of subjects: 1100
Study 19704101 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased Myocardial Perfusion
Number of subjects: 1100
Study 19706858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment for 7 days
Number of subjects: 429
Study 19706886 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 partially HLA-matched UCB units
Number of subjects: 177
Study 19706886 — intervention group
Group type: COMPARATOR
Intervention: 1 partially HLA-matched UCB unit
Number of subjects: 177
Study 19706886 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced disease patients (>= CR3)
Number of subjects: 177
Study 19707564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 99
Study 19708226 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive and invasive findings (clinical interview, 12-lead ECG, 24-h ECG, echocardiogram)
Number of subjects: 500
Study 19708226 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study, pacemaker, implantable cardioverter defibrillator or loop recorder implantation
Number of subjects: 500
Study 19708226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors tested for association with endpoints
Number of subjects: 500
Study 19709990 — intervention group
Group type: EXPERIMENTAL
Intervention: Online dietary intervention (MENU)
Number of subjects: 28460
Study 19710484 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott-Architect Troponin I
Number of subjects: 718
Study 19710484 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche High-Sensitive Troponin T
Number of subjects: 718
Study 19710484 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche Troponin I
Number of subjects: 718
Study 19710484 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Troponin I Ultra
Number of subjects: 718
Study 19710484 — intervention group
Group type: COMPARATOR
Intervention: Standard assay (Roche Troponin T)
Number of subjects: 718
Study 19710484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive assays (within 3 hours of chest pain onset)
Number of subjects: 718
Study 19712484 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus study supports (job aids, non-financial incentives, and supervision)
Number of subjects: 301
Study 19712484 — intervention group
Group type: COMPARATOR
Intervention: Training plus usual supports
Number of subjects: 301
Study 19712484 — intervention group
Group type: COMPARATOR
Intervention: Untrained health workers
Number of subjects: 301
Study 19712484 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supervision frequency
Number of subjects: 301
Study 19712798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1748
Study 19712798 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1748
Study 19712979 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg for 49 days
Number of subjects: 375
Study 19712979 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg after 1 week
Number of subjects: 375
Study 19712979 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR and early Ham-D(17) changes
Number of subjects: 375
Study 19712979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician prediction based on global impression at day 7
Number of subjects: 375
Study 19712979 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum drug levels and genetic polymorphisms (5HTTLPR and 5HT2a)
Number of subjects: 375
Study 19713195 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary Descemet stripping endothelial keratoplasty (DSEK)
Number of subjects: 10
Study 19713456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2)
Number of subjects: 23
Study 19714615 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (1, 4, 10 mg/kg) plus standard of care therapy (SOC)
Number of subjects: 449
Study 19714615 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care therapy (SOC)
Number of subjects: 449
Study 19716045 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 levels in lung transplant recipients (T1 vs T3)
Number of subjects: 191
Study 19716045 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 levels in lung transplant recipients
Number of subjects: 191
Study 19717268 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use
Number of subjects: 499
Study 19717473 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter 3 and 4 repeat alleles
Number of subjects: 0
Study 19717473 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 allele
Number of subjects: 0
Study 19718477 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX3 (upper quartiles)
Number of subjects: 0
Study 19718477 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (upper quartiles)
Number of subjects: 0
Study 19718477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PTX3 and BNP
Number of subjects: 0
Study 19718477 — intervention group
Group type: COMPARATOR
Intervention: hsCRP
Number of subjects: 0
Study 19719485 — intervention group
Group type: EXPERIMENTAL
Intervention: Attain Model 4193 LV lead (Medtronic, Inc)
Number of subjects: 1070
Study 19720420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 1268
Study 19720420 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 1268
Study 19720420 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic White patients
Number of subjects: 1268
Study 19720420 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP increase (1.13 per 5 mm Hg)
Number of subjects: 1268
Study 19720420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 1268
Study 19720420 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy severity
Number of subjects: 1268
Study 19720904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) on days 1 through 21 of a 28-day cycle for six cycles, plus prednisone 30 mg/d during cycle 1, 15 mg/d during cycle 2, and 15 mg/d every other day during cycle 3.
Number of subjects: 40
Study 19720904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and prednisone combination therapy
Number of subjects: 40
Study 19720915 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m(2) once weekly during postoperative weeks 2, 3, and 4) followed by concurrent Paclitaxel (30 mg/m(2)) and Cisplatin (20 mg/m(2)) once weekly during the last 3 weeks of RT (60 Gy over 6 weeks).
Number of subjects: 70
Study 19720915 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Cisplatin with radiation therapy (RT).
Number of subjects: 70
Study 19720915 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative chemoradiotherapy (RTOG 9501).
Number of subjects: 70
Study 19720924 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg twice a day
Number of subjects: 115
Study 19720923 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent trastuzumab and HER2/neu-specific vaccination
Number of subjects: 22
Study 19721480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (180 microg weekly) and ribavirin (800 mg daily) for 14 weeks
Number of subjects: 8
Study 19721480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin treatment
Number of subjects: 8
Study 19723786 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus CBT
Number of subjects: 0
Study 19723786 — intervention group
Group type: COMPARATOR
Intervention: CBT monotherapy
Number of subjects: 0
Study 19723786 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine monotherapy
Number of subjects: 0
Study 19725960 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide (75 mg/m2 during radiotherapy, 150-200 mg/m2 on days 1-5 of each 28-day cycle) with radiotherapy (60 Gy)
Number of subjects: 63
Study 19725960 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide with radiotherapy
Number of subjects: 63
Study 19725960 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin and prolonged Temozolomide with radiotherapy
Number of subjects: 63
Study 19725979 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Day First Grade Program (WD)
Number of subjects: 0
Study 19725979 — intervention group
Group type: COMPARATOR
Intervention: Standard first-grade program (SC)
Number of subjects: 0
Study 19726437 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 2686
Study 19726437 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy in patients treated with IIb/IIIa-inhibitors
Number of subjects: 2686
Study 19726437 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombectomy
Number of subjects: 2686
Study 19726763 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0449 (150 mg per day)
Number of subjects: 33
Study 19726763 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0449 (270 mg per day)
Number of subjects: 33
Study 19726763 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0449 (540 mg per day)
Number of subjects: 33
Study 19726763 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0449
Number of subjects: 33
Study 19727007 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Renin Inhibitors (DRIs)
Number of subjects: 52
Study 19727007 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Renin Inhibitors (DRIs) added to optimal heart failure treatment
Number of subjects: 52
Study 19727007 — intervention group
Group type: COMPARATOR
Intervention: Early generation Direct Renin Inhibitors (DRIs)
Number of subjects: 52
Study 19727007 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent Direct Renin Inhibitors (DRIs)
Number of subjects: 52
Study 19727208 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF)
Number of subjects: 1200
Study 19727657 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms rs34861192 and rs3745368 of RETN
Number of subjects: 3133
Study 19727657 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma resistin level
Number of subjects: 3133
Study 19727665 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. recombinant methionyl human leptin
Number of subjects: 48
Study 19727744 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated whole breast ultrasound (AWBU) plus mammography
Number of subjects: 4419
Study 19727744 — intervention group
Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 4419
Study 19727744 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated whole breast ultrasound (AWBU)
Number of subjects: 4419
Study 19728876 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion (VE) with 500 mL of synthetic colloid
Number of subjects: 38
Study 19728876 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaVpeakbrach >10%
Number of subjects: 38
Study 19728876 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaPPrad >10%
Number of subjects: 38
Study 19728876 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaSVVigileo >11%
Number of subjects: 38
Study 19729666 — intervention group
Group type: EXPERIMENTAL
Intervention: mDC1 and mDC2
Number of subjects: 42
Study 19729666 — intervention group
Group type: EXPERIMENTAL
Intervention: mDC2
Number of subjects: 42
Study 19729666 — intervention group
Group type: EXPERIMENTAL
Intervention: pDC
Number of subjects: 42
Study 19729666 — intervention group
Group type: EXPERIMENTAL
Intervention: mDC1, mDC2, pDC
Number of subjects: 42